Monte Rosa Therapeutics, Inc. Stock Analysis & AI Score
Monte Rosa Therapeutics, Inc. (GLUE) has an ST Score of 45.3 (C+), driven by its Forecast (A) and held back by its Growth (D). Analysts rate it Buy with a $26.67 price target (+127.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Monte Rosa Therapeutics, Inc. (GLUE) has an ST Score of 45.3 (C+), driven by its Forecast (A) and held back by its Growth (D). Analysts rate it Buy with a $26.67 price target (+127.6% upside).
- Strongest
- ForecastA
- Weakest
- GrowthD
All factor grades
- ForecastA
- ProfitabilityB
- Financial StrengthB-
- ValuationC+
- MomentumC-
- GrowthD
- Piotroski2/9
Contact
GLUE stock: frequently asked questions
What is GLUE's ST Score?
Monte Rosa Therapeutics, Inc. (GLUE) has an ST Score of 45.3 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is GLUE a buy, hold, or sell?
Analysts rate GLUE a Buy, with a price target of $26.67 (+127.6% vs the current price). Our ST Score grades it C+ (45.3/100). The ST Score is a data-driven signal, not a recommendation.
What are GLUE's factor grades?
Valuation C+, Profitability B, Financial Strength B-, Momentum C-, Growth D, Forecast A.
What is GLUE's valuation grade?
Monte Rosa Therapeutics, Inc. (GLUE) earns a valuation grade of C+, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is GLUE's growth grade?
Monte Rosa Therapeutics, Inc. (GLUE) earns a growth grade of D, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is GLUE's profitability grade?
Monte Rosa Therapeutics, Inc. (GLUE) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is GLUE's financial strength grade?
Monte Rosa Therapeutics, Inc. (GLUE) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for GLUE?
The average analyst price target for Monte Rosa Therapeutics, Inc. (GLUE) is $26.67 from 9 analysts, which is +127.6% versus the recent price of $11.72.
What is GLUE's Piotroski score?
Monte Rosa Therapeutics, Inc. (GLUE) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.